JP2025508786A5 - - Google Patents
Info
- Publication number
- JP2025508786A5 JP2025508786A5 JP2024549495A JP2024549495A JP2025508786A5 JP 2025508786 A5 JP2025508786 A5 JP 2025508786A5 JP 2024549495 A JP2024549495 A JP 2024549495A JP 2024549495 A JP2024549495 A JP 2024549495A JP 2025508786 A5 JP2025508786 A5 JP 2025508786A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- dose
- administered
- day
- dll3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263313119P | 2022-02-23 | 2022-02-23 | |
| US63/313,119 | 2022-02-23 | ||
| US202263429311P | 2022-12-01 | 2022-12-01 | |
| US63/429,311 | 2022-12-01 | ||
| PCT/US2023/063010 WO2023164474A1 (en) | 2022-02-23 | 2023-02-22 | Cancer treatment targeting dll3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508786A JP2025508786A (ja) | 2025-04-10 |
| JP2025508786A5 true JP2025508786A5 (https=) | 2026-02-24 |
Family
ID=85724660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024549495A Pending JP2025508786A (ja) | 2022-02-23 | 2023-02-22 | Ｄｌｌ３を標的とする癌治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250154247A1 (https=) |
| EP (1) | EP4482586A1 (https=) |
| JP (1) | JP2025508786A (https=) |
| KR (1) | KR20240153575A (https=) |
| AU (1) | AU2023224210A1 (https=) |
| CA (1) | CA3252459A1 (https=) |
| CL (1) | CL2024002529A1 (https=) |
| IL (1) | IL314195A (https=) |
| JO (1) | JOP20240188A1 (https=) |
| MX (1) | MX2024010330A (https=) |
| TW (1) | TW202342096A (https=) |
| WO (1) | WO2023164474A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025080688A1 (en) * | 2023-10-12 | 2025-04-17 | Amgen Inc. | Compositions of bispecific antibody constructs to human dll3 and human cd3 |
| TW202602488A (zh) * | 2024-03-11 | 2026-01-16 | 美商安進公司 | 治療ｄｌｌ３陽性癌症受試者中腦轉移之方法 |
| WO2026008059A1 (en) * | 2024-07-04 | 2026-01-08 | Nanjing Legend Biotech Co., Ltd. | Anti-dll3 constructs and uses thereof |
| WO2026075950A1 (en) * | 2024-10-01 | 2026-04-09 | Amgen Inc. | Dosing regimen for anti-dll3 agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| MXPA06004035A (es) | 2003-10-16 | 2006-08-31 | Micromet Ag | Aglutinantes cd3 de-inmunizados multi-especificos. |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| MX2018002166A (es) * | 2015-08-20 | 2018-09-12 | Abbvie Stemcentrx Llc | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. |
| JP7314146B2 (ja) | 2017-12-28 | 2023-07-25 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| US11976133B2 (en) | 2020-01-31 | 2024-05-07 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| CR20220541A (es) | 2020-03-31 | 2022-11-28 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos |
| IL307646A (en) * | 2021-05-10 | 2023-12-01 | Amgen Inc | Dosing regimen for combination therapy targeting DLL3 and PD-1 |
-
2023
- 2023-02-22 KR KR1020247030821A patent/KR20240153575A/ko active Pending
- 2023-02-22 AU AU2023224210A patent/AU2023224210A1/en active Pending
- 2023-02-22 JP JP2024549495A patent/JP2025508786A/ja active Pending
- 2023-02-22 EP EP23712715.4A patent/EP4482586A1/en active Pending
- 2023-02-22 US US18/836,031 patent/US20250154247A1/en active Pending
- 2023-02-22 MX MX2024010330A patent/MX2024010330A/es unknown
- 2023-02-22 WO PCT/US2023/063010 patent/WO2023164474A1/en not_active Ceased
- 2023-02-22 CA CA3252459A patent/CA3252459A1/en active Pending
- 2023-02-22 IL IL314195A patent/IL314195A/en unknown
- 2023-02-23 TW TW112106776A patent/TW202342096A/zh unknown
-
2024
- 2024-08-19 JO JOJO/P/2024/0188A patent/JOP20240188A1/ar unknown
- 2024-08-23 CL CL2024002529A patent/CL2024002529A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508786A5 (https=) | ||
| JP2024518947A5 (https=) | ||
| JP2022535972A5 (https=) | ||
| Vennepureddy et al. | Novel drugs and combination therapies for the treatment of metastatic melanoma | |
| US8003105B2 (en) | Method of treating cancer by co-administration of anticancer agents | |
| JP2014114288A5 (https=) | ||
| Schwab et al. | Development of hemolytic anemia in a nivolumab-treated patient with refractory metastatic squamous cell skin cancer and chronic lymphatic leukemia | |
| JP2023501375A5 (https=) | ||
| JP2024540275A5 (https=) | ||
| JP2020524670A5 (https=) | ||
| JP2023539625A5 (https=) | ||
| US20200377596A1 (en) | Dosing of bispecific t cell engager | |
| JP2021529777A5 (https=) | ||
| EP3920970B1 (en) | Method for treating checkpoint inhibitors induced adverse events | |
| Melichar et al. | Successful management of infusion reaction accompanying the start of cetuximab therapy | |
| WO2024183817A1 (zh) | 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途 | |
| JP2021528399A5 (https=) | ||
| US20240207199A1 (en) | Fluorocarbon compositions and methods for enhancing immunotherapy | |
| JP2020531437A (ja) | ｈａＮＫセツキシマブ併用及び方法 | |
| Beisel | Alterations in hormone production and utilization during infection | |
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies | |
| CN114040758A (zh) | 使用6,8-双-苄硫基-辛酸治疗淋巴瘤的治疗方法和组合物 | |
| WO2025058453A1 (en) | Methods of treating cancer by administering anti-pd-l1/anti-4-1bb bispecific antibodies | |
| CN112190708A (zh) | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 | |
| WO2019129168A1 (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 |